• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰腺导管腺癌患者不可切除性的预测因素

Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.

作者信息

Okada Ken-ichi, Kawai Manabu, Tani Masaji, Hirono Seiko, Miyazawa Motoki, Shimizu Atsushi, Kitahata Yuji, Yamaue Hiroki

机构信息

Second Department of Surgery, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8510, Japan.

出版信息

J Hepatobiliary Pancreat Sci. 2014 Sep;21(9):648-53. doi: 10.1002/jhbp.109. Epub 2014 Apr 24.

DOI:10.1002/jhbp.109
PMID:24764208
Abstract

BACKGROUND

The aim of the present study was to identify the predicting factors for unresectability and to clarify who should receive precise evaluations for distant metastasis and locally advanced unresectability in patients with pancreatic ductal adenocarcinoma (PDAC).

METHODS

A total of 200 consecutive patients with PDAC who presented to the outpatient clinic between June 2009 and October 2012 were analyzed retrospectively. Clinical factors and the serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, DUPAN-2 (pancreatic cancer-associated antigen) and CA 125 were analyzed.

RESULTS

Of the 200 patients who were investigated for PDAC, 60 (30%) were initially considered unresectable (15 patients with locally advanced tumors, 45 patients with distant metastases). Of the 136 (68%) patients who were surgically explored, 19 (9.5%) were detected to have minute metastases on laparotomy. A multivariate analysis revealed that tumor size (≥30 mm) and abnormalities in the levels of DUPAN-2 and CA 125 were independent predictors of unresectability (P = 0.002, 0.014, < 0.001, respectively). The patients with triple positive findings presented with the highest sensitivity (78.8%) for unresectability.

CONCLUSIONS

Patients with triple positive findings for a tumor size ≥30 mm, abnormalities in the levels of DUPAN-2 and CA 125 should receive precise evaluations for unresectability.

摘要

背景

本研究旨在确定不可切除性的预测因素,并阐明在胰腺导管腺癌(PDAC)患者中谁应接受远处转移和局部晚期不可切除性的精确评估。

方法

回顾性分析了2009年6月至2012年10月期间在门诊就诊的200例连续性PDAC患者。分析了临床因素以及癌胚抗原(CEA)、糖类抗原(CA)19-9、DUPAN-2(胰腺癌相关抗原)和CA 125的血清水平。

结果

在200例接受PDAC检查的患者中,60例(30%)最初被认为不可切除(15例为局部晚期肿瘤,45例为远处转移)。在136例(68%)接受手术探查的患者中,19例(9.5%)在剖腹手术中被检测到有微小转移。多变量分析显示,肿瘤大小(≥30毫米)以及DUPAN-2和CA 125水平异常是不可切除性的独立预测因素(P分别为0.002、0.014、<0.001)。三项阳性结果的患者对不可切除性的敏感性最高(78.8%)。

结论

肿瘤大小≥30毫米、DUPAN-2和CA 125水平异常三项阳性结果的患者应接受不可切除性的精确评估。

相似文献

1
Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.胰腺导管腺癌患者不可切除性的预测因素
J Hepatobiliary Pancreat Sci. 2014 Sep;21(9):648-53. doi: 10.1002/jhbp.109. Epub 2014 Apr 24.
2
Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.血清糖类抗原19.9和杜克胰腺单克隆抗原2对预测胰腺导管腺癌患者血行转移的临床意义
Pancreatology. 2016 Nov-Dec;16(6):1051-1056. doi: 10.1016/j.pan.2016.09.014. Epub 2016 Sep 26.
3
Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.术前 CEA 和 CA 19-9 是可切除性胰腺导管腺癌患者生存的预后标志物——一项回顾性肿瘤标志物预后研究。
Int J Surg. 2013;11(10):1067-72. doi: 10.1016/j.ijsu.2013.10.005. Epub 2013 Oct 23.
4
Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?术前 CA19-9 和 CEA 水平能否预测胰腺腺癌患者的可切除性?
J Gastroenterol Hepatol. 2009 Dec;24(12):1869-75. doi: 10.1111/j.1440-1746.2009.05935.x.
5
Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.伴有同步肝转移的胰腺导管腺癌的术前评估:不可切除性的诊断与评估
World J Gastroenterol. 2016 Dec 7;22(45):10024-10037. doi: 10.3748/wjg.v22.i45.10024.
6
Selective use of staging laparoscopy based on carbohydrate antigen 19-9 level and tumor size in patients with radiographically defined potentially or borderline resectable pancreatic cancer.基于肿瘤标志物 CA19-9 水平和肿瘤大小对影像学界定的潜在可切除或交界可切除胰腺癌患者行分期腹腔镜检查的选择性应用。
Pancreas. 2011 Apr;40(3):426-32. doi: 10.1097/MPA.0b013e3182056b1c.
7
Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal adenocarcinoma.经影像学检查确诊为局部晚期胰腺导管腺癌患者,分期腹腔镜检查发现潜在远处器官转移的危险因素。
J Hepatobiliary Pancreat Sci. 2016 Dec;23(12):750-755. doi: 10.1002/jhbp.408. Epub 2016 Nov 22.
8
Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.胰腺癌患者术前和术后CA19-9、SPan-1及DUPAN-II水平对预后影响的比较
Pancreatology. 2017 Jan-Feb;17(1):95-102. doi: 10.1016/j.pan.2016.10.004. Epub 2016 Oct 11.
9
CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.癌胚抗原(CEA)和糖类抗原19.9(CA-19.9)血清肿瘤标志物作为局部晚期(不可切除)或转移性胰腺腺癌患者的预后因素:一项回顾性分析
J Chemother. 2009 Dec;21(6):673-80. doi: 10.1179/joc.2009.21.6.673.
10
Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.术前血清癌胚抗原和糖类抗原19-9水平用于评估胰腺腺癌患者的可治愈性和可切除性。
J Hepatobiliary Pancreat Surg. 2007;14(6):539-44. doi: 10.1007/s00534-006-1184-3. Epub 2007 Nov 30.

引用本文的文献

1
A pancreatic adenocarcinoma mimicking hepatoid carcinoma of uncertain histogenesis: A case report and literature review.一例组织发生不明的类似肝样癌的胰腺腺癌:病例报告及文献复习
Oncol Lett. 2023 Aug 28;26(4):442. doi: 10.3892/ol.2023.14029. eCollection 2023 Oct.
2
Prognostic Role of Preoperative Duke Pancreatic Monoclonal Antigen Type 2 Levels in Patients with Pancreatic Cancer.术前杜克胰腺癌单克隆抗原 2 型水平对胰腺癌患者的预后作用。
Ann Surg Oncol. 2023 Sep;30(9):5792-5800. doi: 10.1245/s10434-023-13564-7. Epub 2023 May 29.
3
Importance of triple tumor markers as biomarkers in patients with pancreatic ductal adenocarcinoma.
三种肿瘤标志物作为胰腺导管腺癌患者生物标志物的重要性。
Ann Gastroenterol Surg. 2022 Oct 11;7(2):326-335. doi: 10.1002/ags3.12629. eCollection 2023 Mar.
4
The outcome of a multidisciplinary approach incorporating neoadjuvant chemoradiotherapy with S1 for resectable pancreatic ductal adenocarcinoma.多学科方法联合新辅助放化疗与S1治疗可切除胰腺导管腺癌的疗效。
Ann Gastroenterol Surg. 2022 Oct 3;7(2):306-317. doi: 10.1002/ags3.12624. eCollection 2023 Mar.
5
Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer.可切除性胰腺癌患者术中远处转移的预测因素
BMC Gastroenterol. 2018 Nov 6;18(1):168. doi: 10.1186/s12876-018-0891-y.
6
A Panel of CA19-9, Ca125, and Ca15-3 as the Enhanced Test for the Differential Diagnosis of the Pancreatic Lesion.一组CA19-9、Ca125和Ca15-3作为胰腺病变鉴别诊断的强化检测指标。
Dis Markers. 2017;2017:8629712. doi: 10.1155/2017/8629712. Epub 2017 Mar 5.